These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 37759476)

  • 21. NAP alpha-aminoisobutyric acid (IsoNAP).
    Gozes I; Schirer Y; Idan-Feldman A; David M; Furman-Assaf S
    J Mol Neurosci; 2014 Jan; 52(1):1-9. PubMed ID: 24458740
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NAP (davunetide) provides functional and structural neuroprotection.
    Gozes I
    Curr Pharm Des; 2011; 17(10):1040-4. PubMed ID: 21524250
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The cytoskeleton as a drug target for neuroprotection: the case of the autism- mutated ADNP.
    Gozes I
    Biol Chem; 2016 Mar; 397(3):177-84. PubMed ID: 25955282
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The femtomolar-acting NAP interacts with microtubules: Novel aspects of astrocyte protection.
    Gozes I; Divinski I
    J Alzheimers Dis; 2004 Dec; 6(6 Suppl):S37-41. PubMed ID: 15665412
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Microbiota changes associated with ADNP deficiencies: rapid indicators for NAP (CP201) treatment of the ADNP syndrome and beyond.
    Kapitansky O; Giladi E; Jaljuli I; Bereswill S; Heimesaat MM; Gozes I
    J Neural Transm (Vienna); 2020 Feb; 127(2):251-263. PubMed ID: 32072336
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activity-dependent neuroprotective protein deficiency models synaptic and developmental phenotypes of autism-like syndrome.
    Hacohen-Kleiman G; Sragovich S; Karmon G; Gao AYL; Grigg I; Pasmanik-Chor M; Le A; Korenková V; McKinney RA; Gozes I
    J Clin Invest; 2018 Nov; 128(11):4956-4969. PubMed ID: 30106381
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SH3- and actin-binding domains connect ADNP and SHANK3, revealing a fundamental shared mechanism underlying autism.
    Ivashko-Pachima Y; Ganaiem M; Ben-Horin-Hazak I; Lobyntseva A; Bellaiche N; Fischer I; Levy G; Sragovich S; Karmon G; Giladi E; Shazman S; Barak B; Gozes I
    Mol Psychiatry; 2022 Aug; 27(8):3316-3327. PubMed ID: 35538192
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Longitudinal Genotype-Phenotype (Vineland Questionnaire) Characterization of 15 ADNP Syndrome Cases Highlights Mutated Protein Length and Structural Characteristics Correlation with Communicative Abilities Accentuated in Males.
    Levine J; Lobyntseva A; Shazman S; Hakim F; Gozes I
    J Mol Neurosci; 2024 Jan; 74(1):15. PubMed ID: 38282129
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The ADNP derived peptide, NAP modulates the tubulin pool: implication for neurotrophic and neuroprotective activities.
    Oz S; Ivashko-Pachima Y; Gozes I
    PLoS One; 2012; 7(12):e51458. PubMed ID: 23272107
    [TBL] [Abstract][Full Text] [Related]  

  • 30. NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP).
    Gozes I; Morimoto BH; Tiong J; Fox A; Sutherland K; Dangoor D; Holser-Cochav M; Vered K; Newton P; Aisen PS; Matsuoka Y; van Dyck CH; Thal L
    CNS Drug Rev; 2005; 11(4):353-68. PubMed ID: 16614735
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The expression of activity-dependent neuroprotective protein (ADNP) is regulated by brain damage and treatment of mice with the ADNP derived peptide, NAP, reduces the severity of traumatic head injury.
    Gozes I; Zaltzman R; Hauser J; Brenneman DE; Shohami E; Hill JM
    Curr Alzheimer Res; 2005 Apr; 2(2):149-53. PubMed ID: 15974912
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model.
    Vulih-Shultzman I; Pinhasov A; Mandel S; Grigoriadis N; Touloumi O; Pittel Z; Gozes I
    J Pharmacol Exp Ther; 2007 Nov; 323(2):438-49. PubMed ID: 17720885
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NAP, a neuroprotective drug candidate in clinical trials, stimulates microtubule assembly in the living cell.
    Gozes I; Divinski I
    Curr Alzheimer Res; 2007 Dec; 4(5):507-9. PubMed ID: 18220512
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The autism/neuroprotection-linked ADNP/NAP regulate the excitatory glutamatergic synapse.
    Sragovich S; Malishkevich A; Piontkewitz Y; Giladi E; Touloumi O; Lagoudaki R; Grigoriadis N; Gozes I
    Transl Psychiatry; 2019 Jan; 9(1):2. PubMed ID: 30664622
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Single Cell ADNP Predictive of Human Muscle Disorders: Mouse Knockdown Results in Muscle Wasting.
    Kapitansky O; Karmon G; Sragovich S; Hadar A; Shahoha M; Jaljuli I; Bikovski L; Giladi E; Palovics R; Iram T; Gozes I
    Cells; 2020 Oct; 9(10):. PubMed ID: 33086621
    [TBL] [Abstract][Full Text] [Related]  

  • 36. From vasoactive intestinal peptide (VIP) through activity-dependent neuroprotective protein (ADNP) to NAP: a view of neuroprotection and cell division.
    Gozes I; Divinsky I; Pilzer I; Fridkin M; Brenneman DE; Spier AD
    J Mol Neurosci; 2003; 20(3):315-22. PubMed ID: 14501014
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Subcellular localization and secretion of activity-dependent neuroprotective protein in astrocytes.
    Furman S; Steingart RA; Mandel S; Hauser JM; Brenneman DE; Gozes I
    Neuron Glia Biol; 2004 Aug; 1(3):193-9. PubMed ID: 16845437
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NAP (davunetide) enhances cognitive behavior in the STOP heterozygous mouse--a microtubule-deficient model of schizophrenia.
    Merenlender-Wagner A; Pikman R; Giladi E; Andrieux A; Gozes I
    Peptides; 2010 Jul; 31(7):1368-73. PubMed ID: 20417241
    [TBL] [Abstract][Full Text] [Related]  

  • 39. NAP, a peptide derived from the activity-dependent neuroprotective protein, modulates macrophage function.
    Quintana FJ; Zaltzman R; Fernandez-Montesinos R; Herrera JL; Gozes I; Cohen IR; Pozo D
    Ann N Y Acad Sci; 2006 Jul; 1070():500-6. PubMed ID: 16888216
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activity-dependent neuroprotective protein: from gene to drug candidate.
    Gozes I
    Pharmacol Ther; 2007 May; 114(2):146-54. PubMed ID: 17363064
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.